Study on the mechanism of rifaximin alleviating metabolic dysfunction-associated fatty liver disease

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a metabolic disorder arises from the intricate interplay among multiple organs. This process is largely mediated by the interaction of inflammatory cytokines through the gut-liver axis. Rifaximin, with its capacity to modulate the gut microbiota and inflammation, possesses a wide perspective and high potential in the treatment of liver diseases.Therefore, it is of great significance to deeply study the mechanism of rifaximin in improving MAFLAD.